symbol,price,beta,volAvg,mktCap,lastDiv,range,changes,companyName,currency,cik,isin,cusip,exchange,exchangeShortName,industry,website,description,ceo,sector,country,fullTimeEmployees,phone,address,city,state,zip,dcfDiff,dcf,image,ipoDate,defaultImage,isEtf,isActivelyTrading,isAdr,isFund
QURE,6.37,0.957,1063496,304366881,0,5.95-28.255,-0.02,uniQure N.V.,USD,0001590560,NL0010696654,N90064101,NASDAQ Global Select,NASDAQ,Biotechnology,https://www.uniqure.com,"uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-210, a product candidate for the treatment of Parkinson's disease; AMT-260 for temporal lobe epilepsy; AMT-240, a preclinical product candidate for the treatment of autosomal dominant Alzheimer's disease; and AMT-161 for the treatment of amyotrophic lateral sclerosis. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.",Mr. Matthew Craig Kapusta,Healthcare,NL,501,31 20 240 6000,Paasheuvelweg 25a,Amsterdam,,1105 BP,12.2926,33.5326,https://financialmodelingprep.com/image-stock/QURE.png,2014-02-05,False,False,True,False,False
